| 前收盘价格 | 2.92 |
| 收盘价格 | 2.84 |
| 成交量 | 89,465 |
| 平均成交量 (3个月) | 1,925,400 |
| 市值 | 500,642,720 |
| 价格/销量 (P/S) | 1.43 |
| 股市价格/股市净资产 (P/B) | 69.62 |
| 52周波幅 | |
| 利润日期 | 13 Nov 2026 |
| 营业利益率 (TTM) | -6,102.38% |
| 稀释每股收益 (EPS TTM) | -0.260 |
| 总债务/股东权益 (D/E MRQ) | 1.14% |
| 流动比率 (MRQ) | 13.07 |
| 营业现金流 (OCF TTM) | -6.36 M |
| 杠杆自由现金流 (LFCF TTM) | -11.17 M |
| 资产报酬率 (ROA TTM) | -39.60% |
| 股东权益报酬率 (ROE TTM) | -71.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Entera Bio Ltd. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -0.17 |
|
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 24.42% |
| 机构持股比例 | 22.17% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 5,881,879 |
| Bvf Inc/Il | 30 Jun 2026 | 2,425,000 |
| Seven Fleet Capital Management Lp | 30 Jun 2026 | 191,354 |
| Hightower Advisors, Llc | 30 Jun 2026 | 74,573 |
| Signature Estate & Investment Advisors Llc | 30 Sep 2026 | 47,328 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合